We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

To shareholders – according to an analysis of financial reports from healthcare companies.

A Lassa fever vaccine candidate shows promise in animal studies, with guinea pigs 100 percent protected from lethal virus exposure.

A regulatory science push in the UK includes centres for digital transformation, AI and more.

Robert F Kennedy Jr’s recent speech suggests that investigations into childhood vaccines and over-medication could be on the cards.

Early work from Scripps researchers uses a virtual library to synthesize plant-based metabolites: picrotoxanes.

Stakeholders explain why the NIH’s move to cap indirect costs associated with research grants could damage medical innovation.